VFMCRP- ChemoCentryx announce topline data from Phase 2 LUMINA-1 trial

Date: 2020-05-18   Author: Saipriya Iyer  Category: #news

VFMCRP- ChemoCentryx announce topline data from Phase 2 LUMINA-1 trial

VFMCRP (Vifor Fresenius Medical Care Renal Pharma) & ChemoCentryx, Inc. have recently announced the topline data from its 46 patient Phase 2 dose-ranging trial. The trial has been conducted for the orphan kidney disease, primary FSGS (Focal Segmental Glomerulosclerosis).

The trial has tested a CCR2 (the chemokine receptor) selective inhibitor that was orally administered, namely CCX140, in the primary FSGS subjects. The inhibitor did not exhibit a meaningful proteinuria reduction during the trial, in relation to control group following the 12-week blinded treatment.

The primary efficacy measure of the LUMINA-1 trial was a change observed in proteinuria, which is measured by UPCR (urine protein to the creatinine ratio), in 4 groups of blinded treatment (3 active CCX140 doses v/s 1 placebo) from the baseline to 12th week. In the 12th week, all subjects, which include those receiving the placebo, were treated with the CCX140 highest dose. 15 mg of CCX140 twice a day was also offered for an extra 12 weeks of the treatment. Following this, UPCR changes from the week 12th to week 24th have been assessed.

The 15mg dose of CCX140 has exhibited the highest UPCR reduction in the ITT (intent to treat) analysis of the changes of UPCR at week 12 relative to the baseline. The reduction of median from the baseline by over 30% or 0.9 g/g has been observed, with the reduction from the baseline by nearly 25% for geometric mean. Additionally, after the crossover of the blinded portion of this study to 15mg BID dosing, there was no additional UPCR reduction by the previous group of the placebo.

CCX140 was well-tolerated at various doses, with no SAEs (serious adverse events) in the blinded study. It has a numerically lower adverse event rate that emerged from the treatment in the CCX140 group as compared to the placebo group. The complete analysis of the data for the recent trial is in progress, with the expanded results anticipated to be revealed at the medical meeting in 2020.

Source credit:https://www.businesswire.com/news/home/20200517005052/en/VFMCRP-ChemoCentryx-announce-topline-data-phase-II-LUMINA-1



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Cardiac Resynchronization Therapy (CRT) Devices Market to 2026 - Growth Trends and Revenue Statistics

Author: Rahul Varpe

A highly analytical qualitative as well as quantitative evaluation of the Cardiac Resynchronization Therapy (CRT) Devices Market has been covered in this report. The study evaluates the myriad aspects of this industry by taking into consideration ...


Medical Products Market Growth Rate, Revenue and Demand Analysis to 2026

Author: Rahul Varpe

An extremely definite evaluation of the Medical Products Market in terms of qualitative as well as quantitative analysis has been covered in this report. The myriad aspects of this industry, having considered its historical and forecast data have ...


Intensive Care Beds Market - Geography Insights and Opportunity Analysis to 2026

Author: Rahul Varpe

The latest study provides an in-depth analysis of the Intensive Care Beds Market focusing on various market definitions, segmentations, sub-segmentations, products, as well as applications. The report further details of the competitive landscape &...